Acadia Healthcare (NASDAQ:ACHC) Stock Gets Price Target Boost from Barclays

Acadia Healthcare (NASDAQ:ACHC) had its target price boosted by research analysts at Barclays from $32.00 to $35.00 in a research report issued on Thursday, Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Barclays‘s price target points to a potential downside of 5.41% from the stock’s previous close.

ACHC has been the topic of several other reports. Guggenheim increased their price objective on Acadia Healthcare from $38.00 to $39.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Raymond James Financial downgraded Acadia Healthcare from a “strong-buy” rating to an “outperform” rating and set a $39.00 target price for the company. in a research report on Monday, September 28th. KeyCorp upped their target price on Acadia Healthcare from $30.00 to $40.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 14th. Cantor Fitzgerald reiterated a “neutral” rating on shares of Acadia Healthcare in a research report on Tuesday, October 6th. Finally, UBS Group lifted their price target on shares of Acadia Healthcare from $31.00 to $39.00 and gave the stock a “buy” rating in a research note on Thursday, July 9th. Eight analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $32.54.

Acadia Healthcare Price Performance

Shares of NASDAQ ACHC traded up $2.21 during midday trading on Thursday, hitting $37.00. 4,533,735 shares of the company’s stock were exchanged, compared to its average volume of 1,614,038. The company has a current ratio of 1.57, a quick ratio of 1.57 and a debt-to-equity ratio of 1.20. The business’s fifty day moving average price is $29.40 and its two-hundred day moving average price is $26.14. The company has a market cap of $3.44 billion, a price-to-earnings ratio of -2.97, a PEG ratio of 9.54 and a beta of 0.64. Acadia Healthcare has a 12-month low of $11.43 and a 12-month high of $39.38.

Acadia Healthcare (NASDAQ:ACHC) last announced its earnings results on Wednesday, November 4th. The company reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.14. The business had revenue of $895.31 million during the quarter, compared to analyst estimates of $877.76 million. Acadia Healthcare had a negative net margin of 33.44% and a positive return on equity of 6.19%. Acadia Healthcare’s revenue for the quarter was up 5.1% on a year-over-year basis. During the same period in the previous year, the business posted $0.72 earnings per share. As a group, research analysts forecast that Acadia Healthcare will post 1.59 EPS for the current fiscal year.

Institutional Investors Weigh In On Acadia Healthcare

Several institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new position in shares of Acadia Healthcare during the second quarter valued at about $441,685,000. Jefferies Financial Group Inc. bought a new stake in shares of Acadia Healthcare in the second quarter worth about $106,458,000. Deutsche Bank AG purchased a new position in Acadia Healthcare during the 2nd quarter valued at about $49,746,000. First Trust Advisors LP increased its holdings in Acadia Healthcare by 73.0% during the 1st quarter. First Trust Advisors LP now owns 1,689,442 shares of the company’s stock valued at $39,516,000 after purchasing an additional 712,852 shares during the period. Finally, Braidwell LP increased its holdings in Acadia Healthcare by 76.7% during the 2nd quarter. Braidwell LP now owns 1,141,477 shares of the company’s stock valued at $33,708,000 after purchasing an additional 495,577 shares during the period.

Key Stories Impacting Acadia Healthcare

Here are the key news stories impacting Acadia Healthcare this week:

• Positive Sentiment: Acadia reported third-quarter EPS of $0.60, ahead of the $0.46 consensus, and revenue of $895.3 million, above estimates and up 5.1% year over year. The company also raised its full-year guidance, with its outlook described as slightly above expectations. Article
• Positive Sentiment: Guggenheim raised its target to $41 and kept a Buy rating; RBC lifted its target from $31 to $41 and maintained Outperform. These revisions reinforce optimism about further gains. Article Article
• Neutral Sentiment: Cantor Fitzgerald raised its target to $39 but retained a Neutral rating, signaling a more cautious view than the bullish analyst calls. Analyst rating
• Negative Sentiment: Quarterly EPS was below the $0.72 reported a year earlier. Barclays raised its target to $35 but kept an Equal Weight rating; that target is below the cited current share price, suggesting limited upside in its view. Analyst rating

About Acadia Healthcare

Acadia Healthcare Company, Inc is a provider of behavioral healthcare services headquartered in Franklin, Tennessee. The company operates psychiatric hospitals, specialty treatment facilities and outpatient programs focused on mental health and substance use disorders.

Acadia’s services include inpatient and outpatient psychiatric care, addiction treatment, residential treatment, eating-disorder programs, and services for children and adolescents. Its facilities serve patients with a range of behavioral health conditions, including depression, anxiety, trauma-related disorders and substance use disorders.

Founded in 2005, Acadia operates primarily in the United States and also has a significant presence in the United Kingdom through its ownership of Priory, a behavioral healthcare provider.